摘要
目的 探讨曲美他嗪对缺血性心肌病（IHD）收缩功能不全患者的疗效.方法 IHD患者90例,随机分为曲美他嗪组48例以及常规治疗组42例.分别于治疗前和治疗6、12个月检测2组患者血脑钠肽（BNP）含量,心脏彩超测量左心室射血分数（LVEF）、左心室舒张末期内径（LVEDD）,比较其差异.结果 曲美他嗪组治疗6、12个月与治疗前比较,LVEF、LVEDD、BNP显著降低（F 值分别为6.176、4.590、12.357,P均＜0.01）;常规治疗组仅BNP显著降低（F=8.402,P＜0,01）.结论 对于 IHD患者,在常规治疗基础上加用曲美他嗪有助于进一步改善心功能,逆转心室重构.
Objective To evaluate the effect of trimetazidine in ischemic cardiomyopathy patients with impaired systolic function. Methods There were 90 cases in total, and were divided into two groups randomly： 42patients took conventional therapy,and 48 patients took trimetazidine additionally. Plasma levels of brain natriuretic peptide （BNP）, left ventricular ejection fraction（LVEF） and left ventricular end-diastolic dimension（LVEDD） were measured before and after trimetazidine therapy at 6 months, 12 months. Results Compared to conventional therapy group, LVEF, LVEDD and BNP were significantly improved in the trimetazidine group （P 〈 0.01 ）. Conclusions Trimetazidine additional to conventional therapy might improve heart function and reverse ventricles reconstitution in ischemic cardiomyopathy patients with impaired systolic function.
出处
《中国综合临床》
2010年第12期1282-1284,共3页
Clinical Medicine of China
关键词
缺血性心肌病
曲美他嗪
脑钠肽
左心室射血分数
左心室舒张末期内径
Ischemic cardiomyopathy
Trimetazidine
Brain natriuretic peptide
Laft ventricular ejection fraction
Left ventricular end-diastolic dimension
